Lung Cancer Rates Rise Among Never-Smokers and Women as Experts Urge Broadened Screening

POLICY WIRE — Miami, United States — Public perception has long associated lung cancer with older cigarette smokers, but the demographics of the disease have shifted dramatically over the past 15 years toward younger populations, women, and individuals who have never smoked.

Lung cancer now stands as the primary cause of cancer death among women, claiming more lives annually than breast, ovarian, and colorectal cancers combined. Data from the American Lung Association reveals that over the last 44 years, lung cancer rates surged by 79% among women while dropping by 43% for men, resulting in more young women than men receiving diagnoses for the first time.

Public awareness surrounding the rise of the disease among non-smokers intensified following news of Pope Leo XIV’s lung cancer diagnosis on Oct. 13, 2026, as the pontiff reportedly does not smoke. Medical professionals point to environmental exposures and genetics as potential drivers, emphasizing that identifying diverse risk factors regardless of smoking habits is critical for prompt detection and treatment.

When detected in its earliest stages, as seen in the pope’s case, lung cancer can be successfully treated and cured through surgery for both smokers and non-smokers alike. However, current screening guidelines do not account for individuals who have never smoked, meaning tumors frequently go unnoticed until found by chance.

Thoracic oncology experts note that encountering younger women and never-smokers with brand-new diagnoses is an increasingly common clinical experience. Because the disease is unexpected in patients without smoking histories, both individuals and physicians often face frustrating delays before reaching a definitive diagnosis.

Researchers investigating the global trend among women have identified several contributing factors, including the fact that women historically began smoking later than men, thereby shifting their peak window for smoking-related diagnoses. Furthermore, women began smoking during eras when filtered cigarettes were widespread, which altered how tobacco smoke distributed into the outer regions of the lungs to cause adenocarcinoma.

Some scientific literature indicates that women may exhibit higher susceptibility to the carcinogenic dangers of tobacco and secondhand smoke, developing lung cancer after accumulating fewer years of smoking than their male counterparts. Nevertheless, active smokers no longer represent the majority of new diagnoses, with roughly 20% of women battling lung cancer having never touched a cigarette—a proportion higher than that observed in male non-smokers.

Beyond active smoking and secondhand exposure, additional risk factors for the disease include a family history of cancer along with regular contact with asbestos, radon, and general air pollution. Workplace carcinogens such as arsenic, beryllium, cadmium, silica, and nickel remain ongoing health hazards in various global regions, while the long-term cancer risks linked to e-cigarettes and marijuana smoke continue to be evaluated.

Genetics also factor heavily into risk profiles for patients exhibiting a strong familial history of the disease, according to research led by Estelamari Rodriguez, an Associate Director of Community Outreach in Thoracic Oncology at the University of Miami. Investigating these family lineages helps scientists uncover potential susceptibility genes and environmental triggers.

Similar to how BRCA1 and BRCA2 influence breast cancer, alterations in tumor-promoting or tumor-protecting genes can facilitate lung cancer development. Although specific predisposing mutations remain under investigation, examining these familial patterns aids researchers in understanding tumor genesis and formulating novel biomarkers for early detection.

The United States Preventive Services Task Force revised its framework in 2021 to encompass younger patients with lighter smoking histories, recommending annual screenings for adults aged 50 to 80 who have maintained a one-pack-per-day habit for 20 years, alongside current smokers and those who quit within the past 15 years. At-risk women are encouraged to consult physicians regarding low-dose CT scans.

While nationwide breast cancer screenings see participation rates exceeding 70% among eligible women, fewer than 6% of eligible smokers pursue lung cancer screenings. Experts project that the updated criteria will expand screening eligibility for women by 40% by incorporating younger individuals with reduced smoking exposure.

Advancements in understanding genetic mutations and utilizing the body’s immune system have yielded targeted therapies and immunotherapies that significantly improve prognoses for lung cancer patients. Women generally experience more favorable outcomes than men, particularly when they are non-smokers whose tumors exhibit treatable molecular alterations.

Despite these therapeutic strides, female patients frequently experience unrecognized symptoms such as persistent coughing, shortness of breath, profound fatigue, and pain in the back, chest, or shoulders that mimic other health conditions. Because female patients are often diagnosed at a younger age, they may endure symptoms longer before seeking medical help, and physicians might initially overlook lung cancer due to the patient’s youth.

Recognizing early warning signs, broadening eligibility requirements for diagnostic scans, and testing for specific genetic biomarkers represent essential measures in combating the worldwide rise of lung cancer among women.

Reporting by Policy-Wire (PW)